Q-omics provides the consensus-scored MRPL45 profile across patient tissues and cancer cell-line models. MRPL45 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MRPL45 is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, MRPL45 protein abundance shows 19,433 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, KIRP, and LSCC as cancer lineages where MRPL45 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL45 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL45 survival associations across molecular data types. MRPL45 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL45 RNA expression–survival associations across cancer types. High MRPL45 expression shows unfavorable associations in LIHC, HNSC, ACC and BLCA, but favorable associations in KIRC and LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MRPL45 RNA expression.
This table summarizes MRPL45 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPL45. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL45 shows lower tumor expression in KICH and higher tumor expression in KIRP, LIHC, COAD, HNSC and LUAD. The KIRP box plot shows higher MRPL45 RNA expression in tumor versus normal tissue (log2 FC = +0.699, t-test p < 0.001).
This table shows molecular features associated with MRPL45 in patient tissues and cancer cell lines. In patient samples, MRPL45 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL45 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
